Volume | 12,588 |
|
|||||
News | - | ||||||
Day High | 26.41 | Low High |
|||||
Day Low | 24.46 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
XOMA Corporation | XOMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
24.46 | 24.46 | 26.41 | 24.59 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
529 | 12,588 | $ 24.97 | $ 314,344 | - | 13.48 - 27.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:43:42 | 2 | $ 25.49 | USD |
XOMA Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
296.46M | 11.63M | - | 4.76M | -40.83M | -3.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
XOMA News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XOMA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 26.11 | 26.68 | 24.00 | 24.76 | 9,683 | -0.61 | -2.34% |
1 Month | 24.29 | 27.00 | 23.00 | 25.09 | 15,771 | 1.21 | 4.98% |
3 Months | 20.91 | 27.00 | 19.50 | 23.89 | 19,426 | 4.59 | 21.95% |
6 Months | 16.96 | 27.00 | 14.27 | 19.97 | 25,490 | 8.54 | 50.35% |
1 Year | 19.14 | 27.00 | 13.48 | 18.49 | 30,491 | 6.36 | 33.23% |
3 Years | 37.32 | 39.49 | 13.48 | 21.52 | 30,284 | -11.82 | -31.67% |
5 Years | 12.31 | 46.32 | 11.58 | 23.04 | 40,144 | 13.19 | 107.15% |
XOMA Description
XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. |